Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem
A side effect of some cancer treatments commonly referred to as “chemo brain” has received increasing attention from researchers lately. [...]
Groundbreaking Study on How Barrett’s Esophagus becomes Cancer
A new study from Great Britain underscores the importance of early detection of Barrett's Esophagus in the fight to stop [...]
Three New Immunotherapy Indications for Esophageal Cancer Patients
Since March 2021, the U.S. Food and Drug Administration has issued four approvals for PD-L1 Inhibitors for patients with Esophageal [...]
FDA Fast-Tracks Review of 3 New Immunotherapy Options for Esophageal Cancer Patients
The U.S. Food & Drug Administration has granted Priority Review for the use of immunotherapies in three new designations for [...]
New Treatment Option for Patients with HER2+ Gastroesophageal Junction Adenocarcinoma
The U.S. Food & Drug Administration has approved a new therapy for adult patients with locally advanced or metastatic HER2+ [...]
Latest US Stats Show More Esophageal Cancer Cases, Fewer Deaths
The latest statistics released by the American Cancer Society projects that fewer Americans will die of Esophageal Cancer in 2021 [...]
Groundbreaking Immunotherapy Studies in Esophageal Cancer show Significant Benefits
Findings of three studies important to Esophageal Cancer patients were presented at the 2020 ESMO (European Society of Medical Oncology) [...]
Personalized Approach Shows Survival Benefit in Esophageal Adenocarcinoma
Results of a clinical study called PANGEA (Personalized ANtibodies for GastroEsophageal Adenocarcinoma) found survival benefits for patients when compared to [...]
Immunotherapy Breakthroughs for Esophageal Cancer Patients
The early results of two large, Phase III clinical trials of the immunotherapy Opdivo (nivolumab) showed significant survival benefits for [...]
Barrett’s Esophagus and Esophageal Adenocarcinoma can run in Families
The familial connection is one of the Strongest Indicators of Risk according to Experts. ECAN spoke with the Leading Researcher [...]